Resultados da pesquisa - safety one arm ((case r) or (case 2))

Pesquisas alternativas:
safety one » safety zone (Expandir a Pesquisa), safety zones (Expandir a Pesquisa), safety over (Expandir a Pesquisa)
case r » case 1 (Expandir a Pesquisa)
case 2 » case _ (Expandir a Pesquisa), case 1 (Expandir a Pesquisa)

21

Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India

Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India

Por Anvikar, Anupkumar R, Sharma, Bhawna, Shahi, Bhartendu H, Tyagi, Prajesh K, Bose, Tarit K, Sharma, Surya K, Srivastava, Prakriti, Srivastava, Bina, Kiechel, Jean R, Dash, Aditya P, Valecha, Neena
Publicado em 2012

“... rates in intent-to-treat population were 97.51% (94.6-99.1%) in ASAQ and 88.65% (81.3-93.9%) in AQ arms...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

22

Comparative study of extended versus short term thromboprophylaxis in patients undergoing elective total hip and knee arthroplasty in Indian population

Comparative study of extended versus short term thromboprophylaxis in patients undergoing elective total hip and knee arthroplasty in Indian population

Por Nair, Velu, Kumar, Ratheesh, Singh, Bikram Kumar, Sharma, Ajay, Joshi, Gururaj R, Pathak, Kamal
Publicado em 2013

“...: In the prospective arm, only 1 patient developed symptomatic PTE compared to 26 (3.27%) cases of VTE (20 cases of PTE...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

23

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation

Por Lindson, Nicola, Chepkin, Samantha C, Ye, Weiyu, Fanshawe, Thomas R, Bullen, Chris, Hartmann‐Boyce, Jamie
Publicado no Cochrane Database Syst Rev (2019)

“....15 to 1.36, 14 studies, 11,356 participants; I(2) = 4%). Moderate‐certainty evidence, limited by imprecision...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

24

Safety of telephone consultation for "non-serious" emergency ambulance service patients

Safety of telephone consultation for "non-serious" emergency ambulance service patients

Por Dale, J, Williams, S, Foster, T, Higgins, J, Snooks, H, Crouch, R, Hartley-Sharpe, C, Glucksman, E, George, S
Publicado em 2004

“...Objective: To assess the safety of nurses and paramedics offering telephone assessment, triage...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

25

Efficacy and Safety of Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of Uncomplicated Malaria in Ugandan Children

Efficacy and Safety of Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of Uncomplicated Malaria in Ugandan Children

Por Yeka, Adoke, Lameyre, Valerie, Afizi, Kibuuka, Fredrick, Mudangha, Lukwago, Robinson, Kamya, Moses R., Talisuna, Ambrose O.
Publicado no PLoS One (2014)

“... (episodes 2–18), ranged from 88.1% to 98.9% per episode, with no clear difference between the treatment arms...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

26

A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate

A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate

Por Elsakka, Ahmed M., Eltatawy, Hssan H., Almekaty, Khaled H., Ramadan, Ahmed R., Gameel, Tarik A., Farahat, Yasser
Publicado no Arab J Urol (2016)

“...) and haematocrit (from 42.9% to 38.2%) (both P < 0.001). Moreover, one patient in group II had TUR syndrome...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

27

P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM)

P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM)

Por Fujimaki, T., Itoh, K., Terasaki, M., Narita, Y., Arakawa, Y., Sugiyama, K., Nishikawa, R., Aoki, T., Kumabe, T., Nagane, M.
Publicado no Neuro Oncol (2017)

“..., excluding one case of pulmonary embolus. Overall survival of all cases (both vaccine and placebo arms...”
Obter o texto integral
Obter o texto integral

Artigo

28

Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances

Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances

Por Gomes Jr, Claudio AR, Andriolo, Regis B, Bennett, Cathy, Lustosa, Suzana AS, Matos, Delcio, Waisberg, Daniel R, Waisberg, Jaques
Publicado no Cochrane Database Syst Rev (2015)

“... no statistically significant difference in cases where the technique was not reported (RR 0.43, 95% CI 0.13 to 1...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

29

Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face − protocol of a multicenter, prospective, randomized, controlled, two-armed study

Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face − protocol of a multicenter, prospective, randomized, controlled, two-armed study

Por Kohl, E., Koller, M., Zeman, F., Szeimies, R.-M., Philipp-Dormston, W. G., Prager, W., Gerber, P. A., Karrer, S.
Publicado no BMC Dermatol (2017)

“..., prospective, randomized, controlled, two-armed, observer-blinded trial, patients with a minimum of 5 mild...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

30

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without...

Por Perez, Edith A., Suman, Vera J., Davidson, Nancy E., Sledge, George W., Kaufman, Peter A., Hudis, Clifford A., Martino, Silvana, Gralow, Julie R., Dakhil, Shaker R., Ingle, James N., Winer, Eric P., Gelmon, Karen A., Gersh, Bernard J., Jaffe, Allan S., Rodeheffer, Richard J.
Publicado em 2008

“... heart failure [CHF] or cardiac death [CD]) were: Arm A, n=3 (2 CHF, 1 CD); Arm B, n=19 (18 CHF, 1 CD...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

31

Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial

Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial

Por Wilson, Douglas, Goggin, Kathy, Williams, Karen, Gerkovich, Mary M., Gqaleni, Nceba, Syce, James, Bartman, Patricia, Johnson, Quinton, Folk, William R.
Publicado no PLoS One (2015)

“... the plant’s safety has not been objectively studied. An adaptive two-stage randomized double-blind placebo...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

32

Protocol for evaluating the nationwide implementation of the VA Stratification Tool for Opioid Risk Management (STORM)

Protocol for evaluating the nationwide implementation of the VA Stratification Tool for Opioid Risk Management (STORM)

Por Matthew Chinman, Walid F. Gellad, Sharon McCarthy, Adam J. Gordon, Shari Rogal, Maria K. Mor, Leslie R. M. Hausmann
Publicado em 2019-01-01

“... for patients whom STORM identifies as very high-risk (i.e., top 1% of STORM risk scores). Half of VAMCs were...”
Obter o texto integral

Artigo

33

Universal versus conditional day 3 follow-up for children with non-severe unclassified fever at the community level in Ethiopia: A cluster-randomised non-inferiority trial.

Universal versus conditional day 3 follow-up for children with non-severe unclassified fever at the community level in Ethiopia: A cluster-randomised non-inferiority trial.

Por Karin Källander, Tobias Alfvén, Tjede Funk, Ayalkibet Abebe, Abreham Hailemariam, Dawit Getachew, Max Petzold, Laura C Steinhardt, Julie R Gutman
Publicado em 2018-04-01

“... 1) should return to CHWs on day 3 for reassessment. We compared the safety of conditional follow-up...”
Obter o texto integral

Artigo

34

Universal versus conditional day 3 follow-up for children with non-severe unclassified fever at the community level in Ethiopia: A cluster-randomised non-inferiority trial

Universal versus conditional day 3 follow-up for children with non-severe unclassified fever at the community level in Ethiopia: A cluster-randomised non-inferiority trial

Por Källander, Karin, Alfvén, Tobias, Funk, Tjede, Abebe, Ayalkibet, Hailemariam, Abreham, Getachew, Dawit, Petzold, Max, Steinhardt, Laura C., Gutman, Julie R.
Publicado no PLoS Med (2018)

“... 1) should return to CHWs on day 3 for reassessment. We compared the safety of conditional follow-up...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

35

Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin–piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial

Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment...

Por Ahmed, Rukhsana, Poespoprodjo, Jeanne R, Syafruddin, Din, Khairallah, Carole, Pace, Cheryl, Lukito, Theda, Maratina, Sylvia S, Asih, Puji B S, Santana-Morales, Maria A, Adams, Emily R, Unwin, Vera T, Williams, Christopher T, Chen, Tao, Smedley, James, Wang, Duolao, Faragher, Brian, Price, Richard N, ter Kuile, Feiko O
Publicado no Lancet Infect Dis (2019)

“... case detection, with management of febrile cases. METHODS: We did an open-label, three-arm, cluster...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

36

Universal Versus Conditional Third Day Follow-Up Visit for Children With Nonsevere Unclassified Fever at the Community Level in Ethiopia: Protocol for a Cluster Randomized Noninferiority Trial

Universal Versus Conditional Third Day Follow-Up Visit for Children With Nonsevere Unclassified Fever at the Community Level in Ethiopia: Protocol for a Cluster Randomized Noninfer...

Por Källander, Karin, Alfven, Tobias, Workineh, Ayalkibet Abebe, Hailemariam,, Abreham, Petzold, Max, Getachew, Dawit, Barat, Lawrence, Steinhardt, Laura C, Gutman, Julie R
Publicado no JMIR Res Protoc (2018)

“... are randomized to one of the 2 intervention arms; all 144 health posts and 284 community health workers...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

37

Safety of the lateral trauma position in cervical spine injuries: a cadaver model study

Safety of the lateral trauma position in cervical spine injuries: a cadaver model study

Por Hyldmo, P. K., Horodyski, M. B., Conrad, B. P., Dubose, D. N., Røislien, J., Prasarn, M., Rechtine, G. R., Søreide, E.
Publicado no Acta Anaesthesiol Scand (2016)

“... of motion induced by the recovery position, two versions of the HAINES (High Arm IN Endangered Spine...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

38

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins

Por Kumar, Nagi B., Pow-Sang, Julio, Spiess, Philippe E., Park, Jong, Salup, Raoul, Williams, Christopher R., Parnes, Howard, Schell, Michael J.
Publicado no Oncotarget (2016)

“... on the two study arms. Monthly assessments of toxicity (CTCAE 4.0), concomitant medications and organ...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

39

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Por Perkhofer, L., Berger, A. W., Beutel, A. K., Gallmeier, E., Angermeier, S., Fischer von Weikersthal, L., Goetze, T. O., Muche, R., Seufferlein, T., Ettrich, T. J.
Publicado no BMC Cancer (2019)

“..., open label, two-sided phase II study. Within the study, 2 × 46 patients with locally advanced, non...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

40

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study

Por L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein, T. J. Ettrich
Publicado em 2019-10-01

“..., open label, two-sided phase II study. Within the study, 2 × 46 patients with locally advanced, non...”
Obter o texto integral

Artigo